Ex-Biogen R&D chief Al Sandrock lands CEO job at Voyager, taking over the Big Pharma darling in early days of its turnaround strategynews2022-03-22T09:43:58+00:00March 22nd, 2022|FierceBiotech|
Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer fieldnews2022-03-21T20:44:15+00:00March 21st, 2022|FierceBiotech|
Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to RSV vaccine candidate in $225M dealnews2022-03-21T13:08:54+00:00March 21st, 2022|FierceBiotech|
Immunogen’s phase 3 ADC survival data spook investors, sending stock down ahead of FDA filingnews2022-03-21T11:40:29+00:00March 21st, 2022|FierceBiotech|
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’news2022-03-18T18:06:42+00:00March 18th, 2022|FierceBiotech|
Summit says path forward for failed C. difficile drug is likely through partnershipsnews2022-03-18T14:42:46+00:00March 18th, 2022|FierceBiotech|
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readoutsnews2022-03-18T13:24:34+00:00March 18th, 2022|FierceBiotech|
Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trialnews2022-03-18T12:48:26+00:00March 18th, 2022|FierceBiotech|
After megaround, Apexigen inks modest SPAC deal to advance melanoma prospect toward approvalnews2022-03-18T11:28:58+00:00March 18th, 2022|FierceBiotech|
Zosano’s headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmissionnews2022-03-17T20:22:54+00:00March 17th, 2022|FierceBiotech|
